Currently, there are no robust biomarkers that predict immunotherapy outcomes in metastatic melanoma. We sought to build multivariable predictive models for response and survival to anti-programmed ...

Expert panelists consider how to define response to disease-modifying therapies and discuss the threshold for treatment ineligibility due to lack of response. Neil Minkoff, MD: At some point, we are ...